الغذاء و الدواء تعتمد عقار جديد لعلاج النوع الثاني من مرض السكري

The US Food and Drug Administration (FDA) approved linagliptin (Tradjenta, Eli Lilly Co and Boehringer Ingelheim Pharmaceuticals) for improving blood glucose control in adults with type 2 diabetes, either as a stand-alone or in combination with other therapies.

Linagliptin, which comes in tablet form, 

Boehringer Ingelheim and Eli Lilly’s new type II diabetes treatment Tradjenta has been launched in the US.

Tradjenta (linagliptin) is an oral DPP-4 inhibitor that can be used at 5mg as a monotherapy, or in combination with metformin, sulfonylurea or Takeda’s Actos, and is now available is US pharmacies.
Its purpose is to help reduce blood sugar levels in type II diabetics in combination with healthy eating and regular exercise.
The drug, which is in the same class as AstraZeneca and BMS’ Onglyza and Merck’s Januvia, is the first of its kind to be approved at one-dosage strength, even for patients who suffer from kidney or liver impairment.

اعتمدت هيئة الغذاء و الدواء عقار “ليناليبتين” الذي تم انتاجه بشكل مشترك بين شركتي ليلي و بورنجر, و يعد الدواء مساعدا على التحكم بالجلوكوز بالدم للأشخاص البالغين المصابين بالنوع الثاني من السكري. 

boosts the level of hormones that stimulate the release of insulin after a meal by blocking an enzyme called dipeptidyl peptidase-4.

The FDA stated that 8 double-blind, placebo-controlled clinical trials demonstrated

 that the drug is safe and effective in patients with type 2 diabetes. It has been studied as a stand-alone treatment and in combination with other type 2 diabetes therapies, such as metformin, glimepiride (Amaryl, Accord Healthcare), and pioglitazone (Actos, Takeda Pharmaceuticals). However, the combination of linagliptin and insulin has not been studied.

Clinicians should not prescribe linagliptin for patients with type 1 diabetes or those who have diabetic ketoacidosis. The drug’s most common adverse effects are upper respiratory tract infection, stuffy or runny nose, sore throat, muscle pain, and headache

Linagliptin was discovered by Boehringer Ingelheim, based in Ingelheim, Germany. In January, Boehringer Ingelheim and Eli Lilly announced that they would jointly market the medication.